Evidence map›Paper›PMID 42142018›Full record

ArticlePediatric pulmonology2026

Virus Detection and Hospitalization Rate in Infants With Bronchiolitis After Nirsevimab Introduction: A Retrospective Comparative Two-Season Study.

Domenico Paolo La Regina, Mattia Spatuzzo, Enea Bonci, Raffaella Nenna, Laura Petrarca, Maria Giulia Conti, Enrica Mancino, Alessandra Pierangeli, Guido Antonelli, Fabio Midulla

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Pediatric pulmonology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Domenico Paolo La ReginaDepartment of Maternal Child and Urological Sciences, Sapienza University of Rome, Rome, Italy.ORCID https://orcid.org/0000-0002-8297-8920
Mattia SpatuzzoDepartment of Maternal Child and Urological Sciences, Sapienza University of Rome, Rome, Italy.
Enea BonciDepartment of Maternal Child and Urological Sciences, Sapienza University of Rome, Rome, Italy.
Raffaella NennaDepartment of Maternal Child and Urological Sciences, Sapienza University of Rome, Rome, Italy.ORCID https://orcid.org/0000-0001-8880-3462
Laura PetrarcaDepartment of Maternal Child and Urological Sciences, Sapienza University of Rome, Rome, Italy.ORCID https://orcid.org/0000-0002-2430-2981
Maria Giulia ContiDepartment of Maternal Child and Urological Sciences, Sapienza University of Rome, Rome, Italy.
Enrica MancinoDepartment of Maternal Child and Urological Sciences, Sapienza University of Rome, Rome, Italy.
Alessandra PierangeliDepartment of Virology and Microbiology, Sapienza University of Rome, Rome, Italy.ORCID https://orcid.org/0000-0003-0633-360X
Guido AntonelliDepartment of Virology and Microbiology, Sapienza University of Rome, Rome, Italy.
Fabio MidullaDepartment of Maternal Child and Urological Sciences, Sapienza University of Rome, Rome, Italy.

Funding

NextGeneration EU-MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases PE00000007
6 · The paper itself

Abstract

introductionRespiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infections (LRTIs) in infants. In 2024, the monoclonal antibody nirsevimab became available in Italy for all newborns during their first RSV season.

aimsThe aims were to assess whether the introduction of nirsevimab was associated with changes in respiratory virus circulation and hospitalization rates among children admitted with bronchiolitis.

methodsA retrospective study was conducted, comparing two epidemic seasons: pre-nirsevimab (2023-2024) and post-nirsevimab (2024-2025). All infants under 12 months hospitalized for bronchiolitis were included. Viral detection was performed using multiplex PCR on a nasopharyngeal swab. Emergency department visits, pediatric ward, and PICU admissions were analyzed.

resultsA total of 168 patients with bronchiolitis were enrolled across the two epidemic seasons, with 119 cases in the pre-nirsevimab season and 49 in the post-nirsevimab season. Regarding virus circulation, influenza virus cases increased from 5/119 (4.2%) in the pre-nirsevimab season to 7/48 (14.6%) in the post-nirsevimab season. Bocavirus was not detected during the pre-nirsevimab season (0/119) but was identified in 4/48 cases (8.3%) in the post-nirsevimab season. RSV-related hospitalizations decreased in the post-nirsevimab season, corresponding to a 59% reduction (95% CI 0.30-0.57; p < 0.001) in pediatric ward admissions. Similarly, the number of ED visits and PICU admissions for bronchiolitis decreased substantially, with reductions of 52% (95% CI 0.39-0.59; p < 0.001) and 60% (95% CI 0.17-0.99; p < 0.05), respectively. Hospitalized infants were significantly older, with a marked reduction in admissions among those ≤ 3 months of age.

conclusionNirsevimab has proven effective in reducing severe RSV-related bronchiolitis, significantly easing the burden on healthcare systems during RSV epidemics.

Indexed as

Antibodies, Monoclonal, HumanizedAntiviral AgentsBronchiolitisHospitalizationRespiratory Syncytial Virus InfectionsFemaleHumansInfantInfant, NewbornInfluenza, HumanItalyMaleRetrospective StudiesSeasonsAntibodies, Monoclonal, HumanizedAntiviral Agents

Identifiers

PMID42142018
PMCPMC13182760

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.